GlassScriptPhysician profile
Ginger Gabrielle Davis
NPI 1427833789
$2,042.50
in general payments reported to CMS, 2019-2025
34 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $608 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.01 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $149.46 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $147.04 | 2024-2025 | Breztri, Enhertu, Nexium |
| Novo Nordisk INC | $136.11 | 2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Biotech, INC. | $131.56 | 2023-2024 | Tecvayli, Imbruvica, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $126.56 | 2024-2025 | Ninlaro, Trintellix, Alunbrig |
| Xeris Pharmaceuticals, INC. | $99.86 | 2025 | Keveyis |
| Lilly USA, LLC | $80.76 | 2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $78.43 | 2023-2025 | Trelegy Ellipta, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $68.14 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $62.43 | 2025 | Austedo Xr |
| Pfizer INC. | $51.70 | 2025 | |
| Eisai INC. | $47.12 | 2024 | |
| Incyte Corporation | $46.72 | 2023-2024 | Jakafi |
| Daiichi Sankyo INC. | $46.48 | 2024 | Enhertu, Injectafer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.16 | 2024-2025 | Xtandi, Veozah |
| Phathom Pharmaceuticals, INC. | $45.31 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $40.01 | 2023-2024 | Reblozyl, Keytruda |
| Genzyme Corporation | $37.40 | 2023 | |
| Exact Sciences Corporation | $32.31 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.53 | 2025 | Caplyta |
| Seagen INC. | $23.00 | 2023 | Tukysa |
| Lundbeck LLC | $21.82 | 2025 | Rexulti |
| Genmab U.S., INC. | $21.52 | 2023 | Epkinly |
| Novartis Pharmaceuticals Corporation | $21.43 | 2024 | |
| Agios Pharmaceuticals, INC. | $20.72 | 2024 | Pyrukynd |
| Servier Pharmaceuticals LLC | $20.58 | 2024 | |
| Pharmaessentia USA Corporation | $19.69 | 2023 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.60 | 2024 | Gilotrif |
| Puma Biotechnology, INC. | $18.88 | 2024 | |
| Genentech USA, INC. | $18.67 | 2024 | Venclexta |
| Myriad Genetic Laboratories, INC. | $15.36 | 2024 | Myrisk |
| Alexion Pharmaceuticals, INC. | $15.34 | 2024 | Ultomiris |
| Array Biopharma INC | $13.79 | 2024 | Braftovi, Lorbrena, Mektovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.